Q Today, our interview is focusing on the 'timing hypothesis' for estrogen: please can you provide our readers with some background information on this topic?
The 'timing hypothesis' theorizes that estrogen therapy has a more favorable effect in younger women closer to the onset of menopause than in older women, especially in terms of effects on heart disease. There are several lines of evidence that helped to generate this hypothesis, which will be discussed below.
Q What are the cornerstones of the hypothesis? Why is it that estrogen would have positive effects if started early on in the menopause but negative effects if started later?
The main cornerstone is that in a healthy blood vessel, with normal endothelium, the effect of estrogen is to increase synthesis of nitric oxide and to cause the artery to dilate. Other effects are decreased inflammatory cell adhesion to the blood vessel, and an overall decrease in progression of atherosclerotic plaque. However, in a woman who already has advanced atherosclerotic plaque, there is almost a polar opposite effect. The estrogen receptors are not as functional, there is not the same nitric oxide synthesis, there is not vasodilation, and instead of slowing of atherosclerosis there can be an increased risk of rupture of a vulnerable atherosclerotic plaque, and also an increased risk of thrombosis occurring within a narrowed stenotic blood vessel. So, the favorable vascular effects seen in the younger woman in early menopause are absent in the older woman, and there may even be risks related to rupture of vulnerable plaque and thrombo-occlusion of the blood vessel.
Q What evidence is out there to support the hypothesis? Can you tell our readers a little about any trials that have been conducted? 
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There have been several large, prospective, cohort studies, such as the Nurses' Health Study, carried out in tens of thousands of women who initiated hormone therapy close to the onset of menopause, in which a lower risk of heart disease was found in users of hormone therapy compared with nonusers [1] . But, of course, observational studies have many limitations, and results can be confounded by socioeconomic status, access to medical care and lifestyle factors, so we really need to look to randomized clinical trials (RCTs).
There are RCTs in nonhuman primates that suggest that estrogen treatment will slow progression of atherosclerosis if administered soon after the ovaries are removed but not if started many years later [2] . There are also animal studies and bench research studies suggesting that the arteries are more sensitive to estrogen in early menopause than in later menopause [3, 4] .
Such studies suggest that healthy arteries synthesize nitric oxide and vasodilate in response to estrogen [4] .
In the Women's Health Initiative (WHI) Hormone Therapy Trials, the younger women who were aged 50-59 years, or within the first decade since menopause started, had more favorable results with hormone therapy than the women who were more distant from menopause. The younger women tended to have hazard ratios for heart disease below 1, suggesting lower risk, especially in the estrogen-alone trial -where there was close to a 40% lower risk of coronary events, whereas in the older women, there were neutral effects of hormone therapy on heart disease or even an increased risk [5] . So, there was a pattern suggestive of more favorable results for heart disease with hormone therapy in the younger women than in the older women -the adverse events seen in the older women tended to drive the overall unfavorable results for coronary events in the WHI trials.
After the estrogen-alone trial ended, when women aged 50-59 years old had noninvasive imaging of their coronary arteries, the women who had been treated with estrogen had less coronary artery calcium than the women on placebo, and coronary artery calcium is a marker for future risk of cardiovascular (CV) events [6] .
The ELITE trial, preliminary results of which were reported at the American Heart Association Scientific Sessions in November 2014, was an RCT with 643 participants that tested women who were in early menopause (within 6 years of the onset of menopause) versus women who were at least 10 years past the onset of menopause, who were randomized to oral estradiol or to placebo, and followed with noninvasive imaging of carotid intima media thickness. The trial provided evidence that there was slowing of atherosclerosis by carotid ultrasound with estrogen therapy in the younger women but not in the older women, and there was a statistically significant difference between the effect of estrogen in the younger compared with that in the older women that directly supported the timing hypothesis [7] .
The KEEPS trial showed similar rates of progression of atherosclerosis by carotid ultrasound with estrogen versus placebo, but it was a very low-risk study population -the women were all within 3 years of the onset of menopause and there was very little progression of atherosclerosis, so there may have been limited power to detect a difference [8] .
There are therefore myriad lines of evidence that converge to support the timing hypothesis, but there has yet to be a large-scale RCT with clinical events designed to validate the hypothesis. What we have is the WHI, which was not designed for the purpose of testing age differences but did have the statistical power to look at this issue, nonhuman primate and bench research studies, and trials with surrogate end points (such as noninvasive imaging of atherosclerosis progression by carotid ultrasound, as in ELITE).
Although the ELITE trial directly tested the timing hypothesis, it was not large enough to have major clinical events, such as heart attacks, strokes and CV deaths; as a result, it could not prove that the imaging findings would translate into lower risk of CV events in younger women on hormone therapy than in older women. I think that recent results from RCTs have provided a critical mass of research that helps to inform clinical decision-making about hormone therapy. We are able to make use of the timing hypothesis and other information from the randomized trials to carry out risk stratification and personalized risk assessment to help improve safety and overall benefit-risk profiles of hormone therapy.
We now know of several clinical characteristics and biomarkers that have utility in personalized assessment of risk with hormone therapy, and help to identify women who are appropriate candidates and likely to have a favorable benefit-risk profile on hormone therapy versus those women who are not. Those clinical characteristics include age and time since menopause, as well as underlying risk of CV disease such as lipid profile and whether or not there is metabolic syndrome [9] . Women who have obesity, hypertension, diabetes, insulin resistance syndrome, tend to have future science group
The 'timing hypothesis' for estrogen therapy in menopausal symptom management Interview less favorable outcomes, especially with oral estrogen. Some may still be candidates for transdermal (patch) estrogen, which does not go directly to the liver and increase clotting factors and triglycerides. We also have nonhormonal options to manage menopausal symptoms for women who are not good candidates for hormone therapy.
An additional biomarker that may be useful is Factor V Leiden. In the WHI, women who were both overweight and had the Factor V Leiden gene variant had markedly increased risk of venous thrombosis on hormone therapy. Factor V Leiden may therefore have some utility in identifying women at increased risk of venous thrombosis with hormone therapy, but routine screening is not indicated. Also, transdermal preparations may confer lower risk of blood clots than oral estrogen. There is a movement toward transdermal rather than oral delivery of estrogen and this may lead to a more favorable benefit-risk profile in terms of venous thrombosis and possibly stroke risk.
The North American Menopause Society has released a free mobile app called 'MenoPro' that helps clinicians to work together with women in shared decision-making about management of menopausal symptoms [10] . It helps to assess whether or not a woman is a good candidate for hormone therapy, and if not, reviews the options for nonhormonal treatment. The app, which has no industry funding or advertising, contains information about the risks and benefits of treatments and how to go about selecting women who are appropriate candidates for hormonal versus nonhormonal treatment. It has an internal CV disease risk calculator so that you can take into account a woman's 10-year risk for CV disease. Women at high CV risk should avoid HT and are advised to choose nonhormonal options instead. For women with a moderate CV risk score, transdermal estrogen may have advantages over oral estrogen. With respect to nonhormonal treatment options, there is now a US FDA-approved antidepressant for menopausal symptoms (low-dose paroxetine), as well as other nonhormonal medications that have efficacy against hot flashes. So, the good news is that there are many nonhormonal as well as hormonal options for women.
Breast cancer risk should also be taken into account. Women who are at such a high risk of developing breast cancer that they might be candidates for chemoprevention with aromatase inhibitors or tamoxifen are generally not good candidates for hormone therapy. The breast cancer risk calculator in the Meno-Pro app is helpful for determining whether to continue hormone therapy beyond a few years -women who have a higher baseline risk of breast cancer should particularly avoid longer duration of treatment.
Women should also try lifestyle modifications prior to beginning prescription medication and try to identify their triggers for hot flashes, which might be warm beverages, spicy food, alcohol, smoking, warm room temperatures, and so on.
I do want to emphasize that we are talking about the use of hormone therapy for management of menopausal symptoms and we are not recommending that hormone therapy be used for prevention of heart disease or other chronic diseases, because there are known risks -there is an increased risk of venous thrombosis, and there appears to be an increased risk of stroke (even if a small risk), so we are recommending that hormone therapy be used only in the women who have a clear indication for treatment, such as moderate or severe hot flashes, or night sweats, and not for long-term prevention purposes.
I also think it is really important to highlight that the 'absolute risk' of adverse events -the likelihood of having a heart attack, stroke, a CV event or even cancer -is much lower in younger women and women closer to the onset of menopause than in older women, and so what we call the 'attributable' risks from HT are going to be much smaller -in younger than in older women. There are also benefits from hormone therapy that have been identified that could help to counterbalance those small risks -for example, hormone therapy substantially lowers the frequency of hot flashes, reduces the risk of fracture and lowers the risk of being diagnosed with diabetes. So there are some benefits to counter the risks; and, overall, the risks are of small magnitude in younger women. There is a very complex balance of benefits and risks of hormone therapy. But in a younger woman in early menopause who has moderate-to-severe hot flashes and night sweats, and who is in generally good health, the benefits of hormone therapy are likely to outweigh the risks. Hormone therapy continues to have an important clinical role in the management of menopausal symptoms.
Q What direction do you see the field of hormone therapy taking in general over the next 5-10 years?
We need more research on different formulations and different doses of hormones, and the use of transdermal delivery methods. We need to understand whether there is a more favorable benefit-risk profile with the transdermal route and with lower doses of hormonesare they really safer in terms of blood clots, stroke and estrogen-related cancers? It would certainly be helpful to have larger trials of transdermal estradiol and micronized progesterone in younger women in early menopause in order to have a better understanding of the benefits and risks. future science group
There are also other options that include tissue-selective estrogen complexes -the so-called 'TSECs' -such as the new medication with bazedoxifene and estrogen, where you can derive the benefits of estrogen in terms of symptom management and bone health, with what appears to be less risk to the breast and endometrium. I think we need a lot more research in these areas, which represent the latest frontier in terms of menopause management. Most importantly, I think that women need to have options -they need to have access to both hormonal and nonhormonal treatments, and they need to know whether behavioral and integrative medicine approaches, such as paced respiration, acupuncture, and hypnosis, are worth pursuing.
Q What is next for you in this field of work? Do you have any ongoing or future research into the 'timing hypothesis' (or HRT in general) planned?
I am one of the Principal Investigators of the WHI and the KEEPS trials, and we are pursuing a number of additional analyses. We are very much interested in the all-cause mortality and cause-specific mortality findings in the WHI, especially by age, and we are trying to understand whether mortality is a good summary measure of the serious life-threatening conditions. We are doing more detailed analyses of health outcomes according to clinical characteristics, and also incorporating some biomarkers -how helpful are the cardiometabolic biomarkers in identifying women who have more or less favorable outcomes on hormone therapy? In the KEEPS trial, we are interested in looking in more detail at the effects of oral versus transdermal delivery on outcomes, including quality of life, cognitive function and sexual function.
We are interested in pursuing new randomized trials that would include evaluating low-dose oral versus transdermal hormones, different progestogens, as well as the selective estrogen receptor modulators and tissue-selective estrogen complexes. The plans are still in the developmental stage.
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